Skip to main content
Quest Diagnostics

High-Resolution Monitoring of B Cell Isotype Switching for Immuno-Oncology Biomarker Discovery Using the Clinically Validated Quest Diagnostics IGH-LR Assay

AACR 2024

American Association for Cancer Research

San Diego, CA, April 5-10, 2024

Poster presentation: High-Resolution Monitoring of B Cell Isotype Switching for Immuno-Oncology Biomarker Discovery Using the Clinically Validated Quest Diagnostics IGH-LR Assay

Authors: Prathapam R, Champion K, Burkhardt A, Smith CL, Singh R, Looney T

Specialty: Oncology, Genetics

Related content

Audio Podcast
Optimize Oncology Care with Clinical Pathways
Publication
The path to a better biomarker application of a
Publication
Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology
Conference Presentation
Determining the Immune Landscape of Patients with B- and T-cell Malignancies Utilizing Whole Transcriptome RNA Sequencing and TRUST4

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.